AI assistant
Q32 Bio Inc. — Director's Dealing 2023
Mar 6, 2023
34891_dirs_2023-03-06_894cb063-73a4-4277-b4fb-d01a8703bdf8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2023-03-02
Reporting Person: Alloway Paul (See Remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-03-02 | Common Stock | S | 10965 | $1.4467 | Disposed | 16706 | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2022.
F2: This transaction reports the sale of 10,965 shares which were acquired on February 28, 2023 pursuant to the Issuer's Employee Stock Purchase Plan.
F3: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $1.37 to $1.52. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3.